LegoChem Biosciences Inc (141080) - Cash Flow Conversion Efficiency
Based on the latest financial reports, LegoChem Biosciences Inc (141080) has a cash flow conversion efficiency ratio of -0.093x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-46.62 Billion ≈ $-31.60 Million USD) by net assets (₩500.52 Billion ≈ $339.20 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is LegoChem Biosciences Inc's balance sheet to measure how much of total assets are equity-financed.
LegoChem Biosciences Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how LegoChem Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 141080 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
LegoChem Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of LegoChem Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Crane NXT Co
NYSE:CXT
|
-0.011x |
|
Frontken Corporation Bhd
KLSE:0128
|
0.036x |
|
IMMOFINANZ AG
VI:IIA
|
0.061x |
|
Sinomag Technology Co Ltd
SHE:300835
|
0.011x |
|
Foran Energy Group Co Ltd
SHE:002911
|
-0.014x |
|
Changzhou Fusion New Material Co. Ltd. A
SHG:688503
|
N/A |
|
Evergreen Aviation Tech Corp
TW:2645
|
0.059x |
|
LandBridge Company LLC
NYSE:LB
|
0.051x |
Annual Cash Flow Conversion Efficiency for LegoChem Biosciences Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of LegoChem Biosciences Inc from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see LegoChem Biosciences Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩541.12 Billion ≈ $366.71 Million |
₩-124.53 Billion ≈ $-84.39 Million |
-0.230x | -280.65% |
| 2024-12-31 | ₩616.00 Billion ≈ $417.45 Million |
₩78.48 Billion ≈ $53.18 Million |
0.127x | +130.34% |
| 2023-12-31 | ₩148.22 Billion ≈ $100.45 Million |
₩-62.24 Billion ≈ $-42.18 Million |
-0.420x | -1192.20% |
| 2022-12-31 | ₩219.60 Billion ≈ $148.82 Million |
₩-7.14 Billion ≈ $-4.84 Million |
-0.032x | +80.00% |
| 2021-12-31 | ₩258.77 Billion ≈ $175.37 Million |
₩-42.05 Billion ≈ $-28.50 Million |
-0.162x | -22.33% |
| 2020-12-31 | ₩112.13 Billion ≈ $75.99 Million |
₩-14.89 Billion ≈ $-10.09 Million |
-0.133x | -162.66% |
| 2019-12-31 | ₩113.75 Billion ≈ $77.09 Million |
₩24.11 Billion ≈ $16.34 Million |
0.212x | +268.92% |
| 2018-12-31 | ₩101.66 Billion ≈ $68.90 Million |
₩-12.76 Billion ≈ $-8.65 Million |
-0.125x | +26.34% |
| 2017-12-31 | ₩48.21 Billion ≈ $32.67 Million |
₩-8.21 Billion ≈ $-5.57 Million |
-0.170x | +21.52% |
| 2016-12-31 | ₩60.06 Billion ≈ $40.70 Million |
₩-13.04 Billion ≈ $-8.84 Million |
-0.217x | -9.73% |
| 2015-12-31 | ₩43.18 Billion ≈ $29.26 Million |
₩-8.54 Billion ≈ $-5.79 Million |
-0.198x | +49.69% |
| 2014-12-31 | ₩20.04 Billion ≈ $13.58 Million |
₩-7.88 Billion ≈ $-5.34 Million |
-0.393x | -- |
About LegoChem Biosciences Inc
LigaChem Biosciences Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines for unmet medical needs. The company researches and develops products for various therapeutic areas, including antibiotics, anti-fibrotics, immuno-oncology, oncology; and antibody-drug conjugate (ADC) platform technology and small molecule drugs. It also sells medical devic… Read more